心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2014年
4期
449-452
,共4页
心力衰竭,充血性%治疗结果%缬沙坦
心力衰竭,充血性%治療結果%纈沙坦
심력쇠갈,충혈성%치료결과%힐사탄
Heart failure,congestive%Treatment outcome%Valsartan
目的:分析大剂量缬沙坦治疗慢性心力衰竭的临床疗效及安全性。方法:选择我科住院106例慢性心衰患者,根据数字表法随机分为两组:常规剂量组,53例,予以常规剂量(80mg)缬沙坦治疗,1次/d;大剂量组,53例,予以大剂量缬沙坦治疗,80mg,2次/d。两组均按照指南予以抗心衰治疗,疗程6个月。在治疗后测定两组血浆氨基末端脑钠肽前体(NT-proBNP)水平,应用心脏彩色多普勒检测左心室收缩末期内径(LVESd)、舒张末期内径(LVEDd)、室间隔厚度(IVST)和左室后壁厚度(LVPWT)值,以及进行6min 步行试验。分析两组治疗后临床疗效及不良反应发生率。结果:与常规剂量组相比,治疗后大剂量组的 NT-proBNP 水平[(3042.6±116.3)pmol/L 比(2565.8±98.2)pmol/L]及 LVESd [(34.5±2.2)mm 比(29.4±2.0)mm]、LVEDd [(55.1±2.9)mm 比(50.2±2.5)mm]、IVST [(12.9±1.8)mm 比(10.7±1.2)mm]、LVPWT [(11.8±1.1)mm比(10.9±0.9)mm]显著降低(P 均<0.05);大剂量组的6min 步行距离[(271.2±24.9)m 比(367.7±22.3) m]显著增加,治疗总有效率显著升高(43.40%比62.26%)(P 均<0.05),而主要不良反应发生率两组无显著差异(P >0.05)。结论:大剂量缬沙坦治疗慢性心衰更加有效且安全性也较好。
目的:分析大劑量纈沙坦治療慢性心力衰竭的臨床療效及安全性。方法:選擇我科住院106例慢性心衰患者,根據數字錶法隨機分為兩組:常規劑量組,53例,予以常規劑量(80mg)纈沙坦治療,1次/d;大劑量組,53例,予以大劑量纈沙坦治療,80mg,2次/d。兩組均按照指南予以抗心衰治療,療程6箇月。在治療後測定兩組血漿氨基末耑腦鈉肽前體(NT-proBNP)水平,應用心髒綵色多普勒檢測左心室收縮末期內徑(LVESd)、舒張末期內徑(LVEDd)、室間隔厚度(IVST)和左室後壁厚度(LVPWT)值,以及進行6min 步行試驗。分析兩組治療後臨床療效及不良反應髮生率。結果:與常規劑量組相比,治療後大劑量組的 NT-proBNP 水平[(3042.6±116.3)pmol/L 比(2565.8±98.2)pmol/L]及 LVESd [(34.5±2.2)mm 比(29.4±2.0)mm]、LVEDd [(55.1±2.9)mm 比(50.2±2.5)mm]、IVST [(12.9±1.8)mm 比(10.7±1.2)mm]、LVPWT [(11.8±1.1)mm比(10.9±0.9)mm]顯著降低(P 均<0.05);大劑量組的6min 步行距離[(271.2±24.9)m 比(367.7±22.3) m]顯著增加,治療總有效率顯著升高(43.40%比62.26%)(P 均<0.05),而主要不良反應髮生率兩組無顯著差異(P >0.05)。結論:大劑量纈沙坦治療慢性心衰更加有效且安全性也較好。
목적:분석대제량힐사탄치료만성심력쇠갈적림상료효급안전성。방법:선택아과주원106례만성심쇠환자,근거수자표법수궤분위량조:상규제량조,53례,여이상규제량(80mg)힐사탄치료,1차/d;대제량조,53례,여이대제량힐사탄치료,80mg,2차/d。량조균안조지남여이항심쇠치료,료정6개월。재치료후측정량조혈장안기말단뇌납태전체(NT-proBNP)수평,응용심장채색다보륵검측좌심실수축말기내경(LVESd)、서장말기내경(LVEDd)、실간격후도(IVST)화좌실후벽후도(LVPWT)치,이급진행6min 보행시험。분석량조치료후림상료효급불량반응발생솔。결과:여상규제량조상비,치료후대제량조적 NT-proBNP 수평[(3042.6±116.3)pmol/L 비(2565.8±98.2)pmol/L]급 LVESd [(34.5±2.2)mm 비(29.4±2.0)mm]、LVEDd [(55.1±2.9)mm 비(50.2±2.5)mm]、IVST [(12.9±1.8)mm 비(10.7±1.2)mm]、LVPWT [(11.8±1.1)mm비(10.9±0.9)mm]현저강저(P 균<0.05);대제량조적6min 보행거리[(271.2±24.9)m 비(367.7±22.3) m]현저증가,치료총유효솔현저승고(43.40%비62.26%)(P 균<0.05),이주요불량반응발생솔량조무현저차이(P >0.05)。결론:대제량힐사탄치료만성심쇠경가유효차안전성야교호。
Objective:To analyze the clinical therapeutic effect and safety of large dosage of valsartan on chronic heart failure (CHF).Methods:A total of 106 CHF patients hospitalized in our department were chosen and ran-domly divided into routine dose group (n=53,received routine dosage of valsartan,80mg,once/d)and large dose group (n=53,received large dosage of valsartan,80mg,twice/d)accerding to number table.Both groups received anti-heart failure treatment for six months according to the guidelines.After treatment,plasma N terminal pro brain natriuretic peptide (NT-proBNP)level was measured,left ventricular end-systolic diameter (LVESd),left ventricu-lar end-diastolic diameter (LVEDd),interventricular septal thickness (IVST)and left ventricular posterior wall thickness (LVPWT)were measured by color Doppler echocardiography,and all patients received 6min walking test. Therapeutic effect and incidence rates of adverse reactions were compared and analyzed between two groups after treatment.Results: Compared with routine dose group,there were significant reductions in NT-proBNP level [(3042.6±116.3)pmol/L vs.(2565.8±98.2)pmol/L],LVESd [(34.5±2.2)mm vs.(29.4± 2.0)mm], LVEDd [(55.1±2.9)mm vs.(50.2±2.5)mm],IVST [(12.9±1.8)mm vs.(10.7±1.2)mm]and LVPWT [(11.8±1.1)mm vs.(10.9±0.9)mm];significant rise in 6min walking distance [(271.2±24.9)m vs.(367.7 ±22.3)m]and total effective rate (43.40% vs.62.26%)in large dose group,P <0.05 all.There was no signifi-cant difference in incidence rates of major adverse reactions between two groups (P >0.05).Conclusion:Large dos-age of valsartan is more effective and is safe in treatment of chronic heart failure.